CTLA4 and metastatic melanoma: In contrast, there is a large body of evidence that PD-1 and CTLA-4 inhibitors cause systemic inflammation in metastatic melanoma [93], including higher circulating levels of IL-1ra, IL-6, and IL-17, which are associated with irAEs such as colitis and dermatitis [94,95,96,97,98].